3-(4-isothiocyanato-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester | 627463-16-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(4-isothiocyanato-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 3-(4-isothiocyanatophenoxy)piperidine-1-carboxylate
• CAS: 627463-16-5
• 化学式: C₁₇H₂₂N₂O₃S
• 分子量: 334.439
• InChiKey: WSMSYWXDUKEMLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  83.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• DIAMINOTHIAZOLES
  申请人：——

  公开号：US20040006058A1

  公开（公告）日：2004-01-08

  The present invention is directed to novel diaminothiazoles of formula 1 These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

  本发明涉及一种新型的formula1的二氨基噻唑化合物。这些化合物抑制细胞周期依赖性激酶4（Cdk4），并且对Cdk2和Cdk1具有选择性。这些化合物及其药学上可接受的盐和酯具有抗增殖活性，并且在治疗或控制癌症，特别是固体肿瘤方面具有用途。本发明还涉及含有这些化合物的药物组合物，以及治疗或控制癌症的方法，尤其是治疗或控制乳腺、肺部、结肠和前列腺肿瘤的方法。
• DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1507530B1

  公开（公告）日：2005-11-02
• US6818663B2
  申请人：——

  公开号：US6818663B2

  公开（公告）日：2004-11-16
• [EN] DIAMINOTHIAZOLES<br/>[FR] DIAMINOTHIAZOLES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003097048A1

  公开（公告）日：2003-11-27

  The present invention is directed to novel diaminothiazoles of formula (I): These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdkl. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to their use for the preparation of medicaments for the treatment and control of cancer, most particularly the treatment or control of breast, lung and colon and prostate tumors.